Immunology and Cancer Immunotherapy (ICI) The overall goal of the Immunology and Cancer Immunotherapy (ICI) Program is to unite the efforts of basic and clinical immunologists to explore the immune system's impact on cancer development and progression, to develop novel strategies that use immunity to treat cancer, and to conduct clinical trials to test novel therapeutics and approaches to improve patient outcomes and increase overall survival. There are twenty-one members from six different academic departments and two professional schools. The current focus and initiatives of the ICI scientists are centered on three themes: Immune regulation, Immune effector mechanisms, and Translational immunotherapy. The immunotherapy approaches are focused on adoptive T cell therapy, vaccination, and immune regulation blockade. While basic research is a key focus, many faculty members actively are involved in translational bench-to-bedside research. Other members are clinicians (hematologists, oncologists or oncologic surgeons) who actively are involved in clinical research and clinical trials. This program joins established and experienced clinical trialists with NCI-funded cancer immunologists to design, execute, and complete Dartmouth-initiated immunotherapy trials in renal cell carcinoma, melanoma, glioblastoma, colorectal carcinoma, multiple myeloma and hematopoietic stem cell transplantation. There are extensive collaborations between ICI members around common areas of interest in immunobiology and immunotherapy, as evidenced by joint publications and funded grants. Major contributions of the program to the mission of the NCCC have been the facilitation of new insights into the tumor microenvironment and how this is affected by leukocytes, the development of novel protein and cell therapies, the translation of Dartmouth investigator ideas into clinical trials, and the accrual of patients to these trials. NCCC has made substantial commitment to improving the depth and breadth of research and clinical translation of the ICI program through support of shared resources, financial awards for new pilot grants, and strategic recruitment of new investigators. More than 280 cancer-related articles have been published over the reporting period, with 46 (16%) appearing in high impact journals. Intra-programmatic publications (43=15%) involved 19 of our 22 members, and inter-programmatic publications (66=24%) involved 15 members. Total grant funding for the program currently is $6.4M, of which $5.5M is peer-reviewed and $2.2M is from NCI.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dartmouth College
United States
Zip Code
Emond, Jennifer A; Tovar, Alison; Li, Zhigang et al. (2017) FTO genotype and weight status among preadolescents: Assessing the mediating effects of obesogenic appetitive traits. Appetite 117:321-329
Rapuano, Kristina M; Zieselman, Amanda L; Kelley, William M et al. (2017) Genetic risk for obesity predicts nucleus accumbens size and responsivity to real-world food cues. Proc Natl Acad Sci U S A 114:160-165
Carroll, A M; Cheng, R; Collie-Duguid, E S R et al. (2017) Fine-mapping of genes determining extrafusal fiber properties in murine soleus muscle. Physiol Genomics 49:141-150
Fang, Jun; Jia, Jinping; Makowski, Matthew et al. (2017) Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nat Commun 8:15034
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Rothwell, Simon; Cooper, Robert G; Lundberg, Ingrid E et al. (2017) Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis Rheumatol 69:1090-1099
Hampsch, Riley A; Shee, Kevin; Bates, Darcy et al. (2017) Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer. Oncotarget 8:21806-21817
Barr, Paul J; Forcino, Rachel C; Thompson, Rachel et al. (2017) Evaluating CollaboRATE in a clinical setting: analysis of mode effects on scores, response rates and costs of data collection. BMJ Open 7:e014681
Melin, Beatrice S; Barnholtz-Sloan, Jill S; Wrensch, Margaret R et al. (2017) Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 49:789-794
Adachi-Mejia, Anna M; Lee, Chanam; Lee, Chunkuen et al. (2017) Geographic variation in the relationship between body mass index and the built environment. Prev Med 100:33-40

Showing the most recent 10 out of 1659 publications